Gubra A/S (PI3)

Overview

Gubra A/S is an innovative biotech company based in Horsholm, Denmark, operational since 2008. The company is primarily focused on pre-clinical contract research (CRO) services alongside proprietary early target and drug discovery programs. Gubra A/S delivers its expertise globally and leverages its capabilities across two main areas of business: CRO, Discovery & Partnerships, and a dedicated segment of environmentally conscious solutions known as Gubra Green. With specialization in metabolic and fibrotic diseases, Gubra A/S has established a significant partnership with Boehringer Ingelheim for the discovery of novel peptides aimed at combatting obesity, marking its prominence in the biotech industry.

Products and Services

• Pre-clinical Contract Research and Development Services

  Gubra A/S offers comprehensive research and development services targeting metabolic and fibrotic diseases. These services cater to the needs of the pharmaceutical and biotechnology industries, emphasizing in vivo pharmacology, allowing for the testing of drug efficacy and safety in live models.

• Assays and Molecular Pharmacology

  The company provides a diverse range of assays and molecular pharmacology services designed to identify biological targets and understand their roles in diseases. This is crucial for the discovery and development of new pharmaceuticals.

• Bioinformatics, Bioanalysis, and Next Gen Sequencing

  Gubra’s capabilities extend into bioinformatics and bioanalysis, offering valuable insights into genetic data and molecular structures. Next-generation sequencing (NGS) services further enhance its ability to decode complex genetic information, supporting drug discovery and development processes.

• 2D and 3D Imaging Services

  Advanced imaging technologies are utilized to visualize the biomedical status of in vivo and ex vivo samples. These services are instrumental in understanding disease mechanisms and evaluating the effects of therapeutic interventions.

• Partnership with Boehringer Ingelheim

  A landmark collaboration with Boehringer Ingelheim highlights Gubra’s dedication to advancing healthcare through the discovery of novel peptides aimed at treating obesity, a testament to its innovative approach in the biotech sector.

• Gubra Green Segment

  This segment underscores Gubra A/S’s commitment to environmental sustainability within its operations and research activities. The Gubra Green initiative reflects the company’s broader concern for ecological well-being alongside its scientific endeavors.